DUPIXENT Significantly Decreased SNOT-22 Score vs Placebo as
Early as Week 4, With Continued Improvement at Weeks 24 and 52
(Key Secondary Endpoints)1,a
SNOT-22 SCORE IMPROVEMENT AT WEEK 24 with DUPIXENT 300 mg
Q2W + INCS (n=295, pooled DUPIXENT
arms) (-27.77 from a
baseline score of 51.02) vs 19%
improvement with placebo + INCS (n=153) (-10.40 from
a baseline score of 53.48) (LSM difference: -17.36 [95% CI:
-20.87, -13.85]) in SINUS-521
SNOT-22 SCORE IMPROVEMENT SEEN AS EARLY AS WEEK 4 with
DUPIXENT 300 mg Q2W + INCS (n=295,
pooled DUPIXENT arms)
(-19.77 from a baseline score of 51.02) vs
16% improvement with placebo + INCS
(n=153)
(-8.35 from a baseline score of 53.48) (LSM difference: -11.41
[95% CI: -14.78, -8.05]) in SINUS-521
Turn to DUPIXENT to improve a range of CRSwNP symptoms
and QoL measures2
22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0 to 110): reduced score indicates improvement.
a SNOT-22 includes 22 items assessing symptoms and symptom impact associated with CRSwNP. SNOT-22 had a 2-week recall period. The meaningful clinically important difference is 8.9.
QoL, quality of life.